Statin-associated Autoimmune Myopathies: A Pathophysiologic Spectrum

Canadian Journal of Neurological Sciences

Volumn 41, Issue 5, 2014, Pages 638-647

  Wu, Yufan ^a   Lach, Boleslaw ^b   Provias, John P ^b   Tarnopolsky, Mark A ^c   Baker, Steven K ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER CHILDREN S HOSPITAL   (Canada)

Author keywords

autoimmune; HMGCR; myopathy; necrotizing; polymyositis; Statin

Indexed keywords

CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MALE; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; PATHOPHYSIOLOGY; POLYMYOSITIS; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; AUTOIMMUNE DISEASES; CHEMICALLY INDUCED; MIDDLE AGED; MUSCULAR DISEASES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MUSCULAR DISEASES; RETROSPECTIVE STUDIES;

EID: 84944449402     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/cjn.2014.22     Document Type: Article

References (64)

1. Vaughan CJ, Gotto AM, Jr. Update on statins: 2003. Circulation. 2004;110:886-92.
2. Jackevicius CA, Cox JL, Carreon D, et al. Long-term trends in use of and expenditures for cardiovascular medications in Canada. CMAJ. 2009;181:E19-28.
3. Stagnitti MN. Trends in statins utilization and expenditures for the U.S. civilian noninstitutionalized population, 2000 and 2005. Statistical Brief #205. Agency for Healthcare Research and Quality; 2008.
4. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ. 2008;178:576-84.
5. Baker SK, Samjoo IA. A neuromuscular approach to statin-related myotoxicity. Can J Neurol Sci. 2009;35:8-21.
6. Omar MA, Wilson JP. FDA adverse event reports on statinassociated rhabdomyolysis. Ann Pharmacother. 2002;36:288-95.
7. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. 2000;22:441-57.
8. Buettner C, Davis RB, Leveille SG, Mittleman MA, Mukamal KJ. Prevalence of musculoskeletal pain and statin use. J Gen Intern Med. 2008;23:1182-6.
9. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403-14.
10. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther. 2007;29:1761-70.
11. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581-5.
12. Dobkin BH. Underappreciated statin-induced myopathic weakness causes disability. Neurorehabil Neural Repair. 2005;19:259-63.
13. Agostini JV, Tinetti ME, Han L, McAvay G, Foody JM, Concato J. Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc. 2007;55:420-5.
14. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292:2585-90.
15. Soininen K, Niemi M, Kilkki E, Strandberg T, Kivisto KT. Muscle symptoms associated with statins: a series of twenty patients. Basic Clin Pharmacol Toxicol. 2006;98:51-4.
16. Baker SK. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve. 2005;31:572-80.
17. Fauchais AL, Iba Ba J, Maurage P, et al. Polymyositis induced or associated with lipid-lowering drugs: five cases. Rev Med Interne. 2004;25:294-8.
18. Riesco-Eizaguirre G, Arpa-Gutierrez FJ, Gutierrez M, Toribio E. Severe polymyositis with simvastatin use. Rev Neurol. 2003;37:934-6.
19. Giordano N, Senesi M, Mattii G, Battisti E, Villanova M, Gennari C. Polymyositis associated with simvastatin. Lancet. 1997;349: 1600-1.
20. Takagi A, Shiio Y. Pravastatin-associated polymyositis, a case report. Rinsho Shinkeigaku. 2004;44:25-7.
21. Vasconcelos OM, Campbell WW. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve. 2004;30:803-7.
22. Hill C, Zeitz C, Kirkham B. Dermatomyositis with lung involvement in a patient treated with simvastatin. Aust N Z J Med. 1995;25:745-6.
23. Khattak FH, Morris IM, Branford WA. Simvastatin-associated dermatomyositis. Br J Rheumatol. 1994;33:199.
24. Noel B, Cerottini JP, Panizzon RG. Atorvastatin-induced dermatomyositis. Am J Med. 2001;110:670-1.
25. Rodriguez-Garcia JL, Serrano Commino M. Lovastatin-associated dermatomyositis. Postgrad Med J. 1996;72:694.
26. Zuech P, Pauwels C, Duthoit C, et al. Pravastatin-induced dermatomyositis. Rev Med Interne. 2005;26:897-902.
27. Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve. 2010;41:185-90.
28. Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord. 2007;17: 194-200.
29. Dubowitz V, Sewry CA, Hohlfeld R, Dalakas MC. Muscle biopsy: a practical approach; structural and molecular basis of skeletal muscle disease; sporadic inclusion body myositis-diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol. 2006;21;221;437-9, 227;447.
30. Mammen AL. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci. 2010;1184:134-53.
31. Weihl CC, Pestronk A. Sporadic inclusion body myositis: possible pathogenesis inferred from biomarkers. Curr Opin Neurol. 2010;23:482-8.
32. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63:713-21.
33. Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf. 2010;33:171-87.
34. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8:373-418.
35. Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel Curr Med Res Opin. 2011;27:1551-62.
36. Tarnopolsky MA, Pearce E, Smith K, Lach B. Suction-modified Bergstrom muscle biopsy technique: experience with 13,500 procedures. Muscle Nerve. 2011;43:717-25.
37. Dubowitz V, Sewry CA. Histological and histochemical stains and reactions. In: Dubowitz V, Sewry CA, editors. Muscle biopsy: A practical approach. 3rd ed. St. Louis:Saunders Elsevier; 2007. pp. 21-39.
38. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14:337-45.
39. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344-7, 403-7.
40. Hohlfeld R. Polymyositis and dermatomyositis. In: Karpati G, editor. Structural and molecular basis of skeletal muscle diseases. Basel: ISN Neuropath Press; 2002. pp. 221-7.
41. Health, United States. 2010: with special feature on death and dying. Hyattsville, Md.: National Center for Health Statistics, 2011. p. 26.
42. Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 2006;119: 400-409.
43. Schech S, Graham D, Staffa J, et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf. 2007;16:352-8.
44. Rider LG, Miller FW. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA. 2011;305:183-90.
45. Limaye VS, Blumbergs P, Roberts-Thomson PJ. Idiopathic inflammatory myopathies. Intern Med J. 2009;39:179-90.
46. Cox S, Limaye V, Hill C, Blumbergs P, Roberts-Thomson P. Idiopathic inflammatory myopathies: diagnostic criteria, classification and epidemiological features. Int J Rheum Dis. 2010;13:117-24.
47. Chow SC. Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases. Arch Immunol Ther Exp (Warsz). 2009;57:243-51.
48. Gurevich VS, Shovman O, Slutzky L, Meroni PL, Shoenfeld Y. Statins and autoimmune diseases. Autoimmun Rev. 2005;4:123-9.
49. Sailler L, Pereira C, Bagheri A, et al. Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study. Ann Rheum Dis. 2008;67:614-9.
50. Arora M, Chen L, Paglia M, et al. Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells. Proc Natl Acad Sci USA. 2006;103:7777-82.
51. Dunn SE, Youssef S, Goldstein MJ, et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med. 2006; 203:401-12.
52. Stupka N, Tarnopolsky MA, Yardley NJ, Phillips SM. Cellular adaptation to repeated eccentric exercise-induced muscle damage. J Appl Physiol. 2001;91:1669-78.
53. Neal RC, Ferdinand KC, Ycas J, Miller E. Relationship of ethnic origin, gender, and age to blood creatine kinase levels. Am J Med. 2009;122:73-8.
54. Fung EC, Crook MA. Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge. Cardiovasc Ther. 2011;30: e212-8.
55. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62:2757-66.
56. Mammen AL, Amato AA. Statin myopathy: a review of recent progress. Curr Opin Rheumatol. 2010;22:644-50.
57. Khan S, Christopher-Stine L. Polymyositis, dermatomyositis, and autoimmune necrotizing myopathy: clinical features. Rheum Dis Clin North Am. 2011;37:143-58
58. Morikawa S, Murakami T, Yamazaki H, et al. Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins. J Atheroscler Thromb. 2005;12:121-31.
59. Riddoch D, Morgan-Hughes JA. Prognosis in adult polymyositis. J Neurol Sci. 1975;26:71-80.
60. McKown KM. Chapter 86: polymyositis and dermatomyositis. In: Alguire PM, editor. Internal medicine essentials for clerkship students 2. Washington, D.C.:ACP Press; 2009. pp. 317-8.
61. Dalakas MC, Karpati G. Chapter 22: inflammatory myopathies. In: Karpati G, Hilton-Jones D, Bushby K, Griggs RC, editors. Disorders of voluntary muscle. 8th ed. Cambridge:Cambridge University Press; 2010. pp. 427-52.
62. DeVere R, Bradley WG. Polymyositis: its presentation, morbidity and mortality. Brain. 1975;98:637-66.
63. Dalakas MC. Review: an update on inflammatory and autoimmune myopathies. Neuropathol. Appl Neurobiol. 2011;37:226-42.
64. Mahler M, Pierangeli S, Meroni P, Fritzler MJ. Autoantibodies in Systemic Autoimmune Disorders. J Immunol Res. 2014;263-91.